Updates in Advanced Renal Cell Carcinoma from The 2022 International Kidney Cancer Symposium

home / news-network / updates-in-advanced-renal-cell-carcinoma-from-the-2022-international-kidney-cancer-symposium

Hans Hammers, MD, PhD, and Moshe Ornstein, MD, MA, discuss data updates in advanced renal cell carcinoma (RCC) that were presented at the recent 2022 International Kidney Cancer Symposium.

Overview of the Frontline Management and Risk Stratification of Advanced Renal Cell Carcinoma (RCC)

EP. 1: Overview of the Frontline Management and Risk Stratification of Advanced Renal Cell Carcinoma (RCC)

December 15th 2022

Hans Hammers, MD, PhD, describes how patients with advanced renal cell carcinoma are risk-stratified, and the go-to treatment approach for intermediate risk patients.

Comparing IO/IO and IO/TKI Frontline Treatment in Advanced RCC

EP. 2: Comparing IO/IO and IO/TKI Frontline Treatment in Advanced RCC

December 15th 2022

Moshe Ornstein, MD, MA, explains his reasoning for starting patients with advanced renal cell carcinoma on an IO/IO combination regimen.

Updates from the CLEAR Study on Efficacy of Lenvatinib plus Pembrolizumab in Patients with Advanced RCC

EP. 3: Updates from the CLEAR Study on Efficacy of Lenvatinib plus Pembrolizumab in Patients with Advanced RCC

December 22nd 2022

Drs Hans Hammers reviews updated efficacy data on the use of lenvatinib plus pembrolizumab for frontline advanced renal cell carcinoma treatment.

Lenvatinib Dosing Strategies in Frontline Advanced RCC Treatment

EP. 4: Lenvatinib Dosing Strategies in Frontline Advanced RCC Treatment

December 22nd 2022

Hans Hammers, MD, PhD, details his strategies for dosing lenvatinib in patients with advanced renal cell carcinoma.

Nivolumab plus Ipilimumab for Frontline Treatment of Advanced RCC: 5-Year Follow-Up from the CheckMate 214 Trial

EP. 5: Nivolumab plus Ipilimumab for Frontline Treatment of Advanced RCC: 5-Year Follow-Up from the CheckMate 214 Trial

January 9th 2023

Dr Moshe Orenstein reviews the 5-year data update of the CheckMate 214 trial in favorable risk subgroups of advanced renal cell carcinoma.

Managing Adverse Events of IO/IO Frontline Combination Therapies in Advanced RCC Treatment

EP. 6: Managing Adverse Events of IO/IO Frontline Combination Therapies in Advanced RCC Treatment

January 9th 2023

Drs Hammers and Orenstein describe how they manage the side effects of IO/IO combination treatments in their patients with advanced renal cell carcinoma.

COSMIC-313: Frontline Triplet Therapy in Advanced RCC

EP. 7: COSMIC-313: Frontline Triplet Therapy in Advanced RCC

January 16th 2023

Experts discuss data from the COSMIC-313 study investigating a triplet combination therapy for the frontline treatment of advanced renal cell carcinoma.

Emerging Data in Non-Clear Cell RCC Treatment

EP. 8: Emerging Data in Non-Clear Cell RCC Treatment

January 16th 2023

Hans Hammers, MD, PhD, reviews emerging data on the challenging treatment of non-clear cell renal cell carcinoma.

Exciting Investigational Therapies in Advanced RCC

EP. 9: Exciting Investigational Therapies in Advanced RCC

January 23rd 2023

The oncologists close their discussion with a look at some currently ongoing clinical trials in advanced renal cell carcinoma treatment.